BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 34679477)

  • 1. High-Risk Screening for Fabry Disease: A Nationwide Study in Japan and Literature Review.
    Sawada T; Kido J; Sugawara K; Nakamura K
    Diagnostics (Basel); 2021 Sep; 11(10):. PubMed ID: 34679477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fabry disease screening in high-risk populations in Japan: a nationwide study.
    Yoshida S; Kido J; Sawada T; Momosaki K; Sugawara K; Matsumoto S; Endo F; Nakamura K
    Orphanet J Rare Dis; 2020 Aug; 15(1):220. PubMed ID: 32843101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.
    Rosa Neto NS; Bento JCB; Pereira RMR
    Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a Missense Mutation in the α-galactosidase A Gene in a Chinese Family with Fabry Disease.
    Wu Y; Xia H; Yuan J; Xu H; Deng X; Liu J; Zhang H; Deng H
    Curr Genomics; 2018 Jan; 19(1):70-75. PubMed ID: 29491734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Ckd. Qld fabRy Epidemiology (aCQuiRE) study protocol: identifying the prevalence of Fabry disease amongst patients with kidney disease in Queensland, Australia.
    Mallett A; Kearey P; Cameron A; Healy H; Denaro C; Thomas M; Lee VW; Stark S; Fuller M; Hoy WE
    BMC Nephrol; 2020 Feb; 21(1):58. PubMed ID: 32087678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study.
    Inoue T; Hattori K; Ihara K; Ishii A; Nakamura K; Hirose S
    J Hum Genet; 2013 Aug; 58(8):548-52. PubMed ID: 23677059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?
    Duro G; Zizzo C; Cammarata G; Burlina A; Burlina A; Polo G; Scalia S; Oliveri R; Sciarrino S; Francofonte D; Alessandro R; Pisani A; Palladino G; Napoletano R; Tenuta M; Masarone D; Limongelli G; Riccio E; Frustaci A; Chimenti C; Ferri C; Pieruzzi F; Pieroni M; Spada M; Castana C; Caserta M; Monte I; Rodolico MS; Feriozzi S; Battaglia Y; Amico L; Losi MA; Autore C; Lombardi M; Zoccali C; Testa A; Postorino M; Mignani R; Zachara E; Giordano A; Colomba P
    Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30477121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies.
    Ferreira S; Ortiz A; Germain DP; Viana-Baptista M; Caldeira-Gomes A; Camprecios M; Fenollar-Cortés M; Gallegos-Villalobos Á; Garcia D; García-Robles JA; Egido J; Gutiérrez-Rivas E; Herrero JA; Mas S; Oancea R; Péres P; Salazar-Martín LM; Solera-Garcia J; Alves H; Garman SC; Oliveira JP
    Mol Genet Metab; 2015 Feb; 114(2):248-58. PubMed ID: 25468652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational analysis of the GLA gene in Mexican families with Fabry disease.
    Gutiérrez-Amavizca BE; Gal A; Ortíz-Orozco R; Orth U; Prado Montes De Oca E; Gutiérrez-Amavizca JP; Figuera LE
    J Genet; 2017 Mar; 96(1):161-164. PubMed ID: 28360401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene.
    Ferri L; Guido C; la Marca G; Malvagia S; Cavicchi C; Fiumara A; Barone R; Parini R; Antuzzi D; Feliciani C; Zampetti A; Manna R; Giglio S; Della Valle CM; Wu X; Valenzano KJ; Benjamin R; Donati MA; Guerrini R; Genuardi M; Morrone A
    Clin Genet; 2012 Mar; 81(3):224-33. PubMed ID: 21517827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a Novel GLA Gene Mutation, p.Ile239Met, in Fabry Disease With a Predominant Cardiac Phenotype.
    Csányi B; Hategan L; Nagy V; Obál I; Varga ET; Borbás J; Tringer A; Eichler S; Forster T; Rolfs A; Sepp R
    Int Heart J; 2017 May; 58(3):454-458. PubMed ID: 28496025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fabry disease and multiple sclerosis misdiagnosis: the role of family history and neurological signs.
    Colomba P; Zizzo C; Alessandro R; Cammarata G; Scalia S; Giordano A; Pieroni M; Sicurella L; Amico L; Burlina A; Duro G
    Oncotarget; 2018 Jan; 9(8):7758-7762. PubMed ID: 29487688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deficiency in the Screening Process of Fabry Disease: Analysis of Chronic Kidney Patients Not on Dialysis.
    Battaglia Y; Fiorini F; Azzini C; Esposito P; De Vito A; Granata A; Storari A; Mignani R
    Front Med (Lausanne); 2021; 8():640876. PubMed ID: 33634157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional Characterization and Pharmacological Evaluation of a Novel GLA Missense Mutation Found in a Severely Affected Fabry Disease Family.
    Varela P; Mastroianni Kirsztajn G; Ferrer H; Aranda C; Wallbach K; Ferreira da Mata G; Moura LA; Moreira SR; Mendes C; Curiati MA; Martins AM; Bosco Pesquero J
    Nephron; 2020; 144(3):147-155. PubMed ID: 31665721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Screening of Fabry Disease in Male Hemodialysis Patients in Brazil Highlights Importance of Family Screening.
    Silva CA; Barreto FC; Dos Reis MA; Moura Junior JA; Cruz CM
    Nephron; 2016; 134(4):221-230. PubMed ID: 27576502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of novel Fabry disease-associated pathogenic variants in Japanese patients by newborn and high-risk screening.
    Sawada T; Kido J; Sugawara K; Matsumoto S; Takada F; Tsuboi K; Ohtake A; Endo F; Nakamura K
    Mol Genet Genomic Med; 2020 Nov; 8(11):e1502. PubMed ID: 33016649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of α-galactosidase cross-correction in Fabry heterozygote cultured skin fibroblasts.
    Fuller M; Mellett N; Hein LK; Brooks DA; Meikle PJ
    Mol Genet Metab; 2015 Feb; 114(2):268-73. PubMed ID: 25468650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel α-galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease.
    Duro G; Musumeci MB; Colomba P; Zizzo C; Albeggiani G; Mastromarino V; Volpe M; Autore C
    Gene; 2014 Feb; 535(2):365-9. PubMed ID: 24140492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLA missense and promoter variants co-segregating in a Chinese family with Fabry disease.
    Dong ZY; Wang Q; Lin SP; Chen P; Liu JN; Liu SW; Cai GY; Chen XM; Hong Q
    Ann Transl Med; 2020 Jul; 8(14):865. PubMed ID: 32793709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying Fabry patients in dialysis population: prevalence of GLA mutations by renal clinic screening, 1995-2019.
    Capuano I; Garofalo C; Buonanno P; Pinelli M; Di Risi T; Feriozzi S; Riccio E; Pisani A
    J Nephrol; 2020 Jun; 33(3):569-581. PubMed ID: 31650418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.